CCR5 cell surface density and HIV-1 envelope sequences govern antiretroviral potency of CCR5 antagonists

被引：0
|
作者：
Miller, MD
Lineberger, JE
Dornadula, G
Danzeisen, RC
Blau, CR
Danovich, RM
Miller, MA
Finke, PE
Oates, BD
Caldwell, CG
Chen, P
Meurer, LC
Mills, SG
Springer, MS
Petropoulos, CJ
Whitcomb, J
Huang, W
Fransen, S
Simon, AJ
Hazuda, DJ
机构：
[1] Merck Res Labs, Dept Biol Chem, West Point, PA USA
[2] Merck Res Labs, Dept Microbial Vaccine Res, West Point, PA USA
[3] Dept Med Chem, Rahway, NJ USA
[4] Dept Immunol & Rheumatol, Rahway, NJ USA
[5] ViroLog Inc, San Francisco, CA USA
来源：
ANTIVIRAL THERAPY | 2003年 / 8卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
61
引用
收藏
页码：U66 / U67
页数：2
相关论文
共 50 条
  • [1] CCR5 antagonists in the treatment of treatment-experienced patients infected with CCR5 tropic HIV-1
    Lorenzen, Thore
    Stoehr, Albrecht
    Walther, Irene
    Plettenberg, Andreas
    EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2007, 12 (09) : 419 - 425
  • [2] CCR5 antagonists in the treatment of treatment-naive patients infected with CCR5 tropic HIV-1
    Bredeek, U. Fritz
    Harbour, Michael J.
    EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2007, 12 (09) : 427 - 434
  • [3] CCR5 promoter polymorphism determines macrophage CCR5 density and magnitude of HIV-1 propagation in vitro
    Salkowitz, JR
    Bruse, SE
    Meyerson, H
    Valdez, H
    Mosier, DE
    Harding, CV
    Zimmerman, PA
    Lederman, MM
    CLINICAL IMMUNOLOGY, 2003, 108 (03) : 234 - 240
  • [4] Primary genotypic resistance of HIV-1 to CCR5 antagonists in CCR5 antagonist treatment-naive patients
    Soulie, Cathia
    Malet, Isabelle
    Lambert-Niclot, Sidonie
    Tubiana, Roland
    Thevenin, Monique
    Simon, Anne
    Murphy, Robert
    Katlama, Christine
    Calvez, Vincent
    Marcelin, Anne-Genevieve
    AIDS, 2008, 22 (16) : 2212 - 2214
  • [5] The promise of CCR5 antagonists as new therapies for HIV-1
    Repik, Alexander
    Richards, Kathryn H.
    Clapham, Paul R.
    CURRENT OPINION IN INVESTIGATIONAL DRUGS, 2007, 8 (02) : 130 - 139
  • [6] Differential Use of CCR5 by HIV-1 Clinical Isolates Resistant to Small-Molecule CCR5 Antagonists
    Henrich, Timothy J.
    Lewine, Nicolas R. P.
    Lee, Sun-Hee
    Rao, Suhas S. P.
    Berro, Reem
    Gulick, Roy M.
    Moore, John P.
    Tsibris, Athe M. N.
    Kuritzkes, Daniel R.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2012, 56 (04) : 1931 - 1935
  • [7] How will CCR5 antagonists influence the recommendations for the antiretroviral treatment of HIV-1 infection
    van Lunzen, Jan
    EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2007, 12 (09) : 435 - 440
  • [8] CCR5 HIV-1 vertical transmission
    Shearer, WT
    Kalish, LA
    Zimmerman, PA
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 1998, 17 (02): : 180 - 181
  • [9] Allosteric regulation of CCR5 by guanine nucleotides and HIV-1 envelope
    Staudinger, R
    Wang, XH
    Bandrés, JC
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2001, 286 (01) : 41 - 47
  • [10] The envelope gene is a cytopathic determinant of CCR5 tropic HIV-1
    Olivieri, Kevin
    Scoggins, Robert M.
    Bor, Yeou-cherng
    Matthews, Aprille
    Mark, David
    Taylor, James R., Jr.
    Chernauskas, David
    Hammarskjold, Marie-Louise
    Rekosh, David
    Camerini, David
    VIROLOGY, 2007, 358 (01) : 23 - 38
12345